Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.
You may also be interested in...
User Fees For FY 2017 Make Sponsors Happy, Manufacturers Sad
Several facility fees will increase next year as application fees drop.
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Time and again, FDA officials had to explain the importance of the analytical characterization data in the biosimilar development paradigm.
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
Fee rates for biosimilars could be decoupled from new drug user fees in order to provide more predictable revenue stream.